Best clinical decision support AI

A buyer asking this question is usually shown a list of products that answer clinical questions, and only some of them are decision support. The AI Health Index draws the line on a testable property rather than on marketing language. A decision support product answers what to do for this patient, takes the chart as input, and inherits the evidentiary and regulatory obligations a patient specific output carries. A reference product answers what the evidence says, needs little or no patient context to do it, and several vendors in that category process no protected health information at all.

That distinction is not academic. It decides whether clearance is a live question, whether a business associate agreement is required, and whether subgroup performance is something you have to ask about. Products that genuinely do both are graded on both and cross listed rather than being forced onto one side.

Applying that rule leaves 148 vendors, and their composition is the finding: only 26 are primarily decision support companies. Counts are of vendors, as of August 31, 2026.

Read that table as a procurement warning rather than as taxonomy. Most decision support does not arrive through a decision support purchase. It arrives inside an imaging contract, a medication safety module, a monitoring deployment or a reference subscription, which means it is frequently bought by a committee that never evaluated it as decision support at all and never asked the questions this page is built around.

It also means a category level comparison is the wrong instrument on its own. If your candidate is primarily an imaging product, read it against the imaging roster too, and use the comparison view to put two records side by side on all 15 axes.

Every vendor in the index carries a grade on all 15 axes before it is published at all, so this table compares the same questions answered for every vendor rather than the results of uneven research.

The top of the table is what the category sells: 92 vendors earn the top grade on how central the model is to the product, and both of the axes a clinical buyer would name next, evidence and regulatory status, carry real numbers rather than token ones. This is a more mature answer than the same table produces for most categories in this index.

The bottom is what the category does not publish. Pricing, subgroup performance, model provenance and accountability sit at the floor, and those four are the questions a buyer cannot answer from a vendor website and will not be handed in a demo. They are worth taking into the room precisely because a prepared answer is unlikely.

In most categories the FDA and Regulatory Status axis records an absence. Ambient documentation drafts a note a clinician signs, so it sits outside device regulation and not one scribe vendor in this index earns a top grade on that axis, which is the expected answer rather than a warning sign.

Decision support is the exception, and it is the reason this page reads differently from the scribes guide. Here 46 vendors earn the top grade, and the products that carry clearance carry it because they make a patient specific claim that regulation treats as a device function. On this axis the grade separates rather than flattens, so a buyer can use it.

Two cautions before using it as your only filter. Clearance is not evidence of benefit in your setting: it establishes that a claim was reviewed for a stated intended use and population, which may not be yours. And an uncleared product is not automatically out of scope, because the non device exclusion for clinical decision support genuinely applies to some products here, and where a vendor asserts it the right question is on whose reading, since a clinician has to be able to independently review the basis of the output for that exclusion to hold.

The useful move is to require both claims at once. 27 of 148 vendors hold the top grade on regulatory status and published evidence together, and that intersection is a far better starting shortlist than either axis alone.

Not one vendor in this category earns a top grade on AI Liability and Recourse, and 38 sit at the bottom grade. The strongest records here are vendors that publish terms at all, and those terms typically offer the service as is, disclaim warranties, and leave the clinician holding the decision.

Before reading that as a decision support failing, note the scale of it. Across all 554 vendors in this index, spanning every category, exactly 1 earns a top grade on that axis. It is the clearest single finding this index has produced and it is an industry position rather than a category one.

It lands harder here than anywhere else, though, and the reason is the output. A documentation error surfaces in a note a clinician reads and signs. A decision support error surfaces as a recommendation, a risk score or a suppressed alert that changes what happens to a patient, and it can be right on average while being wrong about a particular person. Accountability for that is not transferred by the standard contract.

The practical consequence is short and it belongs in the deployment plan rather than the negotiation. Decide what your review step is, who staffs it, and what it catches, then choose the product that fits it. A vendor that describes its oversight model clearly is easier to build that step around than one that scores well on everything else.

Each list below is every vendor in the category holding the top grade on the named axes. They are not ranked, they are alphabetical, and a vendor appearing on none of them is not disqualified. It has not published what these axes ask for, which is a question to raise rather than a verdict.

If more than one of these is your failure mode, take the intersection yourself rather than looking for a vendor that appears on every list. Almost none do, which is the point of the next section.

The widest record in the category holds a top grade on 8 axes of 15. The median record holds 2. There is no vendor here that clears every bar, and a comparison built on the assumption that one exists will end in a tie broken by brand recognition.

A low count is not a verdict on a product. Several of the strongest clinical performers in this roster are narrow specialists that publish deeply on the two axes their buyers care about and say nothing on the rest, and they should not be read as worse than a platform that publishes shallowly on many.

What the spread does tell you is how many finalists to carry. Two or three vendors that clear your one non negotiable axis will produce a better process than ten that all look plausible on a feature grid, and it is a faster process too.

Every clinical decision support vendor in the index, each graded on all 15 axes with a source and a date on every judgement. Inclusion is not purchasable and no vendor pays for placement or review.